Shire earnings jump but sales disappoint

Drug maker Shire lifted first-quarter earnings 10 per cent but revenues missed consensus estimates by 5.0 per cent.

Drug maker Shire lifted first-quarter earnings 10 per cent but revenues missed consensus estimates by 5.0 per cent.

Product sales in the three months to end-March 2013 were up 1.0% to $1.1bn against a strong set of comparatives from the equivalent period in 2012, but this was less than analysts were expecting.

Advertisement - Article continues below

Sales of Replagal for sufferers of Fabry disease fell 15% due to issues with shipments and competition, while the restructuring of the sales and marketing model for Dermagraft foot ulcer treatment saw its sales fall 62%.

Compensating for these falls, Dublin-headquartered Shire enjoyed particularly strong performances from Vyvanse for children with attention-deficit disorder (ADHD), hyperactivity treatment Intuniv and Lialda for colitis, leading to group earnings advancing 10% to $1.63 per share on a non-GAAP basis and generating $257m of cash during the quarter.

As he set out his strategy for Shire's future, new Chief Executive Officer Flemming Ornskov said: "Shire has consistently delivered growth significantly above the industry levels of mid single digit and we intend that this will be the case in the future."

Ornskov's growth strategy is to sharpen the group's focus on "commercial excellence" of currently marketed products and "pipeline innovation" through research and development and business development.

Broker Jefferies notes that management are confident in meeting earnings forecasts of $6.67 earnings per ADS, but are now targeting lower sales growth due to weaker Replagal and Dermagraft.

The broker said: "As a growth story we believe lower top-line momentum [will] drive stock weakness, but longer-term valuation and pipeline drive our 'buy'."

Shares in Shire were down 6.4% at 1,890p at 15:20 on the day of the announcement.




Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular


House price crash: UK property prices are falling – so where next?

With UK property prices falling for the first time in eight years, are we about to see a house price crash? John Stepek looks at what’s behind the sli…
2 Jul 2020

The end of the bond bull market and the return of inflation

Central bank stimulus, surging post-lockdown demand and the end of the 40-year bond bull market. It all points to inflation, says John Stepek. Here’s …
30 Jun 2020

Have small companies lost their edge?

SPONSORED CONTENT – The tectonic plates beneath the modern investing landscape appear to have started moving in new directions
26 Jun 2020